Poster Abstract Session:
115. Antimicrobial Chemotherapy
Friday, October 19, 2012: 12:30 PM-2:00 PM
Room: SDCC Poster Hall F-H

Topical Category: C. Clinical Studies and J. Clinical Practice Issues

Tracks: Adult ID, Pediatric ID

Presentations:

773
Comparison of Vancomycin and Daptomycin MICs by Testing Method and Media Source for Contemporary Isolates of Methicillin-Resistant Staphylococcus aureus
Carmen L. Giltner, PhD. ; April M. Bobenchik, PhD. ; Daniel Z. Uslan, MD, MS ; Janet A. Hindler, MCLS, MT ; Romney M. Humphries, Ph.D.

774
Clinical Evaluation of Pentoxifylline Administration on Amphotericin B Nephrotoxicity
Jeremy Sen, PharmD ; Bryan Alexander, PharmD ; Scott Heysell, MD, MPH ; Heather Cox, PharmD ; Costi Sifri, MD ; Brian Wispelwey, MD

775
Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae in Community Hospitals: A Case-Case-Control Study
Grace Lee, Pharm.D ; Donna R. Burgess, RPh ; Kurt Winkler, Pharm.D ; Eugene Kreys, Pharm.D ; David S. Burgess, PharmD, FCCP

776
Epidemiology and Risk Factors of Breakthrough Infections in Patients Receiving Carbapenem Therapy
Sireethorn Nimitvilai, MD ; Nasikarn Angkasekwinai, MD ; Methee Chayakulkeeree, MD, PhD

777
Comparison of Outcomes and Costs in Patients with Urinary Tract Infections (UTI) or Pneumonia (P) with Treatment Initiated in a Physician Office Infusion Center (POIC) versus those Treated After Hospital Discharge
John S. Adams, MD ; Andrew H. Krinsky, MD ; Jorge R. Bernett, MD ; Robin H. Dretler, MD, FIDSA ; Juan D. Diaz, DO, FACP ; Lucinda J. Van Anglen, PharmD

778
Impact of an Infectious Diseases-Hospitalist Cellulitis Consult Service on Antimicrobial Use and Hospitalization Costs
Kristine Johnson, MD, MSc ; Dmitry Kiyatkin, MD ; Karen Daniels, MS, CRNP ; Janet McIntyre, RN, MSN, CPHQ ; Jonathan M. Zenilman, MD, FIDSA
Posters
  • for upload.pdf (311.7 kB)

  • 779
    Safety and Clinical Outcomes of Daptomycin at Doses of ≥10 mg/kg
    Kristine C. Willett, PharmD ; Dina Besece, PharmD ; Alicia Desilets, PharmD ; Patrick McDaneld, PharmD ; Jessica Moreno, PharmD ; MinJung Yoon, MPH ; Kenneth C. Lamp, PharmD

    780
    Antibiotic Timing: Potential Impact on the Correct Diagnosis of Community-Acquired Pneumonia in the Emergency Department
    Fanny Ita-Nagy, MD ; Marnie Rosenthal, DO, MPH ; Gregg Husk, MD ; Donna Mildvan, MD ; Jorg Ruhe, MD

    781
    Impact of Guideline-Concordant Antibiotic Therapy in Critically-Ill Healthcare-Associated Pneumonia Patients
    Russell T. Attridge, PharmD, MSc ; Christopher R. Frei, PharmD, MSc ; Marcos I. Restrepo, MD, MSc ; Mary Jo V. Pugh ; Antonio Anzueto, MD ; Eric M. Mortensen, MD, MSc

    783
    The State of Infectious Diseases Clinical Trials: A Systematic Analysis of ClinicalTrials.gov
    Neela D. Goswami, MD ; Christopher Pfeiffer, MD ; John Horton, MS ; Karen Chiswell, PhD ; Asba Tasneem, PhD ; Ephraim Tsalik, MD PhD

    784
    Efficacy and safety of moxifloxacin in patients with secondary peritonitis: pooled analysis of four randomised Phase III clinical trials
    Jan De Waele, MD PhD ; Jose Tellado ; Jeffrey D. Alder, PhD ; Frank Kruesmann ; Pierre Arvis ; Tajamul Hussain ; Joseph Solomkin, MD

    785
    Extended Infusion (EI) Compared to Standard Infusion (SI) Cefepime as Empiric Treatment of Febrile Neutropenia (FN): A Pilot Study
    Rebekah Wrenn, PharmD ; David Cluck, PharmD ; LeAnne Kennedy, PharmD ; Christopher Ohl, MD ; John Williamson, PharmD
    Posters
  • IDSA Cefepime SI vs EI 2012.pdf (420.7 kB)

  • 786
    Evaluation of Clinical and Economic Outcomes when Meropenem and Piperacillin-Tazobactam are Administered as Extended Compared to Intermittent Infusions in Critically Ill Adults
    Lacy Ternes, PharmD ; Kati Shihadeh, PharmD ; Kimberly Boeser, Pharm D ; Richard Mandt, PharmD ; Bruce Lohr, PharmD ; Robert Leduc, PhD
    Posters
  • IDWeek Poster.pdf (1.1 MB)

  • 787
    Accuracy of Vancomycin Monitoring in Children
    Becky Ngu, PharmD ; Edmund Capparelli, PharmD ; John S. Bradley, MD, FIDSA ; William Murray, PharmD ; Gale Romanowski, PharmD ; Jennifer Le, PharmD, BCPS-ID, FCCP

    788
    Pharmacokinetics (PK) of Daptomycin (DAP) in Pediatric Patients 3 to 24 Months of Age: Implications for Dosing
    John S. Bradley, MD, FIDSA ; David Benziger, PhD ; Paula Bokesch, MD ; Richard Jacobs, MD

    790
    Comparison of Treatment Outcomes for Oral Vancomycin Capsules vs. Solution for Severe C. difficile Infection (CDI)
    Elizabeth A. Neuner, PharmD ; Stephanie Bass, PharmD ; Seth Bauer, PharmD ; Simon Lam, PharmD

    791
    Therapeutic Drug Monitoring (TDM) of Voriconazole (VCZ) in Pediatric Patients
    Jennifer M. Pisano, MD ; Emily Landon, MD ; Benjamin D. Brielmaier, PharmD ; Natasha N. Pettit, PharmD, BCPS ; Allison H. Bartlett, MD

    792
    Outpatient Incidence, Treatment and Recurrence of Clostridium difficile Infection (CDI) in Patients Receiving Intravenous Antibiotic Therapy (IVAB) in a Physician Office Infusion Center (POIC)
    Ramesh V. Nathan, MD ; Barry Statner, MD ; Philip Brachman, MD, FACP, FIDSA ; Andrew H. Krinsky, MD ; Robin H. Dretler, MD, FIDSA ; Lucinda J. Van Anglen, PharmD

    793
    Outcomes Comparison of Intravenous Antimicrobials Provided in a Physician Office Infusion Center (POIC) versus Traditional Home Care (HC) Services
    Richard C. Prokesch, MD, FACP, FIDSA ; John S. Adams, MD ; Alfred E. Bacon, III, MD ; Philip Brachman, MD, FACP, FIDSA ; Lucinda J. Van Anglen, PharmD

    794
    Adverse Events and Healthcare Utilization during Home Infusion Therapy with Daptomycin and Vancomycin
    Nabin Shrestha, MD, MPH, FIDSA ; Pamela Mason, RN ; Steven Gordon, MD, FIDSA, FSHEA ; Anil K. Jain, MD ; Elizabeth A. Neuner, PharmD ; Benjamin Nutter ; O'Rourke Colin ; Susan J. Rehm, MD
    Posters
  • IDSA poster.pdf (194.0 kB)

  • 797
    Satisfaction and Outcomes of Patients Discharged on Intravenous Antibiotics With and Without a Formal OPAT Program at a Tertiary Referral Center
    Katie Sharff, MD ; Joe Fazio, RPh, MHA ; Anne Jacob, MD ; Alex Leahey, MD ; Claire Zeigler, MD ; Penelope Barnes, MBBS, Ph.D

    799
    Incidence of Adverse Events During Outpatient Antimicrobial Therapy in Patients from an Inner-City, County Teaching Hospital
    Cole Beeler, MD ; Christina E. K. Chung, PharmD ; Danielle Osterholzer, M.D. ; Eva Muloma, MD ; Sharon Erdman, PharmD
    Posters
  • Slide1.jpg (3.1 MB)

  • 801
    Adherence to Laboratory Monitory Recommendations and Readmission or Death in a Community-based Parenteral Anti-infective Therapy (CoPAT) Program
    Daniel Huck ; Jennifer Ginsberg ; Steven Gordon, MD, FIDSA, FSHEA ; Amy Nowacki, PhD ; Nabin Shrestha, MD, MPH, FIDSA
    Posters
  • Huck_CoPATPoster_IDWeek.pdf (123.2 kB)

  • 803
    Safety of Midlines vs. PICC lines for Outpatient Parenteral Antibiotic Therapy (OPAT)
    Geneve Allison, MD ; Xibei Jia, Medical Student ; Yoav Golan, MD MS

    805
    A national survey of Outpatient Parenteral Anti-microbial Therapy (OPAT) practices in the United States – Focus on patient safety
    Eavan Muldoon, MB, BCh, MD ; Karen Switkowski, MS, MPH ; Alan Tice, MD, FACP, FIDSA ; David Snydman, MD, FIDSA ; Geneve Allison, MD
    Posters
  • OPATIDSAfinal.pdf (1.1 MB)

  • 807
    Providing Long-Term Intravenous Antimicrobial Therapy to Uninsured Inpatients at an Urban Safety-Net Hospital
    Katayoun Rezai, MD ; G Itokazu, PharmD ; Robert Glowacki, PharmD ; Laura Wahlfeldt, RN, BSN, ACM ; David Schwartz, MD
    Posters
  • opat abstract final.pdf (973.6 kB)

  • 808
    Risk factors for complications during OPAT therapy
    Kimberly Felder, MSc, PA-C ; Matthew Dehart, BSc ; Michael Lasarev, MSc ; Lynn Marshall, Ph.D ; Penelope Barnes, MBBS, Ph.D
    Posters
  • OPAT Complications - Poster.pdf (146.8 kB)

  • 809
    Investigation of Nonconvulsive Status Epilepticus Associated with Cefepime Use
    P Kim, MD MS ; John Farley, M.D., M.P.H. ; T Smith, MD ; Sumathi Nambiar, MD MPH

    810
    Piperacillin/Tazobactam-Induced Neutropenia in Children - a Cohort Study
    Pierre Lemieux, B.Pharm ; Roseline Thibeault, MD ; Jean-Pierre Grégoire, PhD ; Luc Bergeron, B.Pharm, M.Sc.

    811
    Infectious Diseases Physician Management of Antibiotic Allergies
    Lilian Abbo, MD ; Susan E. Beekmann, RN, MPH ; Philip M. Polgreen, MD ; Birgir Johannsson, MD ; Antoine Azar, MD ; Thomas M. Hooton, MD

    812
    Utilization of Vancomycin Serum Concentrations in the Hospitalized Pediatric Patient
    Jennifer Goldman, MD ; Leslie Stach, PharmD, BCPS ; Kevin Mroczka, MHA ; David Williams, MPH ; Stephen De Lurgio, PhD ; Keith Mann, MD, MEd ; Angela Myers, MD, MPH

    813
    Evaluation of a Vancomycin Dosing Nomogram based on the Modification of Diet in Renal Disease Equation in Critically Ill Patients
    Brandy Golenia, PharmD ; Alexander Levine, PharmD ; Iman Moawad, PharmD ; D.Dante Yeh, MD ; Paul Arpino, PharmD

    815
    The use of N-acetylcysteine for the reversal of hepatotoxicity induced by anti-tuberculosis drugs
    Heta Javeri, MD, MPH ; Jason E. Bowling, MD ; Gregory Anstead, MD, PhD
    Posters
  • IDSANACposter10_4_PDF.pdf (257.9 kB)

  • 816
    Hypoglycemia in Patients Treated with Linezolid
    Prabha Viswanathan, MD ; Dmitri Iarikov, MD ; Ronald Wassel, PharmD ; Alma Davidson, MD ; Sumathi Nambiar, MD MPH
    Posters
  • LZD HYPO poster IDSA 2012.pdf (58.2 kB)

  • 818
    Efficacy and Safety of Oral Vancomycin (V) Versus Oral Metronidazole (M) for Treatment of Clostridium difficile Associated Diarrhea (CDAD): Pooled Results from Two Randomized Clinical Trials
    Stuart Johnson, MD, FIDSA ; Dale Gerding, MD, FIDSA ; David Davidson, MD ; Thomas J Louie, M D ; Oliver A Cornely, MD, FIDSA ; David Fitts ; Stephen Gelone, PharmD ; Colin Broom, MD

    819
    Risk Factors Associated with Renal Dysfunction in Children Treated with Intravenous Acyclovir: a Case Control Study
    Suchitra Rao, MB, BS ; Mark J Abzug, MD ; Phyllis Carosone-Link, MSPH ; Tori Peterson, PharmD ; Danielle Soranno, MD ; Georgette Siparsky, PhD ; Jason Child, PharmD ; Eric A.F. Simoes, MB BS, DCH, MD
    Posters
  • ACV IDSA abstract 10.4.12.jpg (783.2 kB)

  • 820
    A Retrospective Review of Pharyngeal Gonorrhea Clinical Failures to Cefixime in Two STI Clinics in Alberta, Canada
    Jennifer Gratrix, RN, MSc ; Joshua Bergman, RN, BScN ; Ron Read, MD ; Marguerite Lovgren, MLT, ART ; Steven J. Drews, PhD ; Ameeta Singh, BMBS, MSc

    821
    Incidence of Toxicity with High-Dose Trimethoprim-Sulfamethoxazole in a VA Medical Center
    Ann Nguyen, Pharm.D. ; Chris Gentry, Pharm.D. ; Rona Furrh, Pharm.D.
    Posters
  • TMPSMXposterv4.pdf (529.9 kB)
  • CME Credits:


    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.